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OBJECTIVE: This study sought to outline the clinical and laboratory characteristics of minimal change disease in
adolescents and adults and establish the clinical and laboratory characteristics of relapsing and non-relapsing patients.
METHODS: We retrospectively evaluated patients with confirmed diagnoses of minimal change disease by renal
biopsy from 1979 to 2009; the patients were aged .13 years and had minimum 1-year follow-ups.
RESULTS: Sixty-three patients with a median age (at diagnosis) of 34 (23-49) years were studied, including 23 males
and 40 females. At diagnosis, eight (12.7%) patients presented with microscopic hematuria, 17 (27%) with
hypertension and 17 (27%) with acute kidney injury. After the initial treatment, 55 (87.3%) patients showed
complete remission, six (9.5%) showed partial remission and two (3.1%) were nonresponders. Disease relapse was
observed in 34 (54%) patients who were initial responders (n = 61). In a comparison between the relapsing patients
(n = 34) and the non-relapsing patients (n = 27), only proteinuria at diagnosis showed any significant difference (8.8
(7.1-12.0) vs. 6.0 (3.6-7.3) g/day, respectively, p=0.001). Proteinuria greater than 7 g/day at the initial screening was
associated with relapsing disease.
CONCLUSIONS: In conclusion, minimal change disease in adults may sometimes present concurrently with
hematuria, hypertension, and acute kidney injury. The relapsing pattern in our patients was associated with basal
proteinuria over 7 g/day.
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INTRODUCTION
Minimal change disease (MCD) is the leading cause of
nephrotic syndrome in children under the age of 10,
accounting for 90% of all cases. In adults, however, MCD
accounts for only 9-15% of primary glomerulopathy cases
(1-3), and studies in adults are scarce, likely due to the lower
disease incidence in this age group. Waldman et al.
observed that at the time of diagnosis, in addition to the
classic nephrotic presentation of glomerulopathy, 43% of
patients presented with hypertension, 17.8% had acute
kidney injury, and 29% had microscopic hematuria (4). It
was also observed that the treatment response was favor-
able. However, relapses are frequent and may range from
62.3 to 73.1%, with corticosteroid dependence in 12% of
cases and corticosteroid resistance in 4.8 to 27% of cases (4-
6). This relapsing characteristic has led some authors to seek
diagnostic markers that can be used to differentiate
relapsing from non-relapsing patients, and some studies
have indicated that adults with early presentation of the
disease and high serum levels of IgE are more likely to
relapse (5,6).
A study in adult Chinese patients also found elevated
serum IgE levels in relapsing patients (7), and these findings
were explained by the fact that serum IgE levels reflected
immune dysfunction as well as B- and T-cell activation (7).
The absence of studies on this pathology in the Brazilian
population led us to conduct a retrospective study aimed at
identifying the clinical and laboratory characteristics of
primary onset MCD in a patient population over the age of
13 and establishing the clinical and laboratory character-
istics of relapsing versus non-relapsing patients.
MATERIALS AND METHODS
We retrospectively evaluated patients who had been
diagnosed with nephrotic syndrome and MCD, as con-
firmed by renal biopsy, from 1979 to 2009 in two university
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centers in the State of Sa˜o Paulo, Brazil (Hospital das
Clı´nicas da Faculdade de Medicina da Universidade de
Sa˜o Paulo and Universidade Estadual Paulista-School of
Medicine-Hospital das Clı´nicas of Botucatu).
Inclusion Criteria
The following inclusion criteria were established: an
initial clinical presentation of nephrotic syndrome; a
diagnosis of MCD that was confirmed by renal biopsy
using conventional criteria with normal light microscopy
and negative immunofluorescence in a representative
sample; age greater than 13 years; and follow-up time of
at least 1 year.
Exclusion Criteria
Patients diagnosed with any systemic disease, such as
systemic lupus erythematosus or other autoimmune dis-
eases, diabetes, or previous hypertension were excluded, as
were those with less than 1 year of follow-up. To confirm
these data, all of the patients were tested for ANA, viral
serology, and blood glucose, and they also received an
ophthalmological review or an echocardiogram.
From 1979 to 2009, 102 renal biopsies confirmed the
diagnoses of MCD in the proposed patient group. Thirty-
nine patients were excluded from the analysis; ten were
discharged to their original medical units and 29 missed
their follow-up appointments during this period.
The patient data were obtained through an analysis of
medical records and included clinical characteristics,
laboratory parameters, response to medical treatment and
relapses.
After an initial treatment, proteinuria ,0.3 g/day was
defined as complete remission; the reduction of baseline
proteinuria by .50% with a final value ,3 g/day was
defined as partial remission; and resistance was defined as
cases where no remission occurred after the use of
immunosuppressive medication for up to 16 weeks.
Relapse was defined as proteinuria values that returned to
.3 g/day after a remission period; immunosuppressive
medication dependence was defined as relapses occurring
within four weeks after withdrawal; and acute kidney injury
(AKI) was defined as an increase of 50% or more in the
baseline creatinine level.
Hematuria was defined as more than eight red blood cells
per high-power field. Hypertension was defined as systolic
blood pressure or diastolic blood pressure .139 mmHg or
90 mmHg, respectively, in two sequential readings.
This study was approved by the Nephrology Department
of the Universities of Sa˜o Paulo and Botucatu as well as the
university ethics committee.
Statistical Analysis
The continuous variable data were expressed as the
median with quartile intervals and percentages for catego-
rical variables. Differences between the two groups were
evaluated using the unpaired Student’s t-test; when the
sample was not normally distributed, we applied the Mann-
Whitney U-test. Categorical variables between groups were
evaluated using the chi-squared test. Logistic regression
was tested for a dependent variable (relapse) in relation to
the independent variables (patient age at diagnosis, serum
albumin and proteinuria). The level of statistical significance
was set at p,0.05.
RESULTS
We studied 63 patients with a median age at diagnosis of
34 (23-49) years, including 23 males and 40 females. The
biochemical data at diagnosis showed levels of serum
creatinine of 0.8 (0.7-1.3) mg/dL, serum albumin of 1.8
(1.5-2.3) g/dL, proteinuria of 7.2 (5.3-10.3) g/day, total
cholesterol of 423.0 (335.0-524.0) mg/dL and triglycerides of
214.5 (162.5-310.5) mg/dL. At the time of diagnosis, eight
(12.7%) patients presented with microscopic hematuria, 17
(27%) had hypertension and 17 (27%) had acute kidney
injury. The mean follow-up time for these patients was 24
(17-60) months.
The decision to treat and the choice of the treatment
regimen were made by the assistant nephrologist in
accordance with clinical criteria. In the initial treatment,
most patients (52, 82.5%) were treated only with predni-
sone at 1 mg/kg/day for eight weeks with gradual
tapering thereafter; three (4.7%) patients received cyclos-
porine; two (3.1%) were given prednisone and cyclopho-
sphamide; and six (9.5%) received no immunosuppression
because they presented with spontaneous remission. After
the initial treatment, 55 (87.3%) patients demonstrated
complete remission, six (9.5%) presented with partial
remission and two (3.1%) were nonresponders. In the
patients with remission (n = 61), relapse occurred in 34
(54%) patients with a median of two (1-3) relapses per
patient during the follow-up period. Two of these patients
(3.1%) were considered dependent on immunosuppressive
medication.
Comparing the clinical presentation at diagnosis between
the groups of patients with relapse (n = 34) and without
relapse (n = 27), there was no difference in age (32.5 (22.5-
46.0) vs. 34.0 (23.0-61.0) years, respectively), gender, clinical
presentation (hematuria, hypertension and acute kidney
injury) and follow-up time (Table 1). In the initial laboratory
data, there was a statistically significant difference only in
proteinuria, which was greater in the relapsing group than
in the non-relapsing group (8.8 (7.1-12.0) vs. 6.0 (3.6-7.3) g/
day, p= 0.001, respectively) (Table 1).
In a logistic regression, only proteinuria affected the
relapse frequency, with an odds ratio of 1.23 (p = 0.01; 95%
CI 1.04 to 1.46). However, the patient age at diagnosis and
the serum albumin level did not show any effect on relapse
(Table 2). For the patients with proteinuria .7 g/day (at
diagnosis), 27 (44.2%) were in the relapse group, and 11
(18%) were in non-relapse group (p= 0.002). In contrast, only
seven (11.4%) of the patients with proteinuria #7 g/day (at
diagnosis) were in the relapse group.
Sixty-five percent of patients received non-immunosup-
pressive agents for renin-angiotensin system-blocking ther-
apy, and 45% received statin therapy. There was no
difference in the use of these medications between the
relapsing and non-relapsing patients.
At the end of the follow-up period, there were no
differences between the groups with and without relapse
regarding the levels of serum creatinine (0.8 (0.7-0.9) vs. 0.8
(0.6-0.9) mg/dL, respectively), proteinuria (0.1 (0.07-0.3) vs.
0.1 (0.06-0.3) g/day, respectively), triglycerides (97 (66-129)
vs. 102 (70-141.5)) mg/dL, respectively) and total cholesterol
(193.0 (158.0-216.0) vs. 191.0 (168.5-223.0) mg/dL, respec-
tively). During this period, one patient in the relapse group
presented with loss of renal function but did not require
dialysis.
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The following complications occurred during the follow-
up period. In the group without relapse, one patient
developed diabetes mellitus, and another developed mela-
noma. In the group with relapse, three patients developed
diabetes mellitus, two had osteoporosis, two had depres-
sion, and one developed obesity.
DISCUSSION
This study assessed retrospective data from two uni-
versity centers over a 30-year period and found that
minimal change disease in adults affected a patient
population in their third decade of life (34 (23-49) years);
only nine patients were aged 60 years or older (data not
shown), and there was a slight predominance of females
(1.7/1). The disease evolution was favorable; however, one
patient developed chronic kidney disease, and one patient
aged 70 years was diagnosed with melanoma close to
glomerulopathy symptoms.
Our patients were similar to those observed in other
studies in terms of age at the onset of disease, gender and
the presence of hematuria at diagnosis (4,8). However, as
compared to other study protocols, our study evaluated
fewer patients with hypertension and proteinuria at
diagnosis and a higher frequency of patients with acute
kidney injury at diagnosis (4,8).
The clinical presentation of acute kidney injury in MCD is
associated with acute tubular necrosis in most cases and
occurs more frequently in older hypertensive patients (4,9).
In the present study, the AKI patients were older than those
without AKI (48.0 (34.0-60.0) vs. 29.0 (22.0-41.0) years,
p = 0.015), but there was no difference in hypertension,
proteinuria and serum albumin level between these groups
(data not shown).
The response to initial treatment with glucocorticoster-
oids for this pathology is generally high, approximately
80% (4,10), and our data revealed a total 96.8% remission
rate, including complete remissions (87.3%) and partial
remissions (9.5%). However, relapse is an important
characteristic of this disease, as it occurred in 54% of the
cases in our study. Nine patients (14.2%) experienced more
than two relapses during the follow-up period, and two of
these patients were considered dependent on immunosup-
pressive medication (Figure 1). Other studies have also
shown a high frequency of relapse, with values between
67.1 and 73.1% (4,5,11).
It would be beneficial to establish clinical and laboratory
characteristics to differentiate relapsing from non-relapsing
patients, with the aim of using steroids for a shorter period
of time and calcineurin inhibitors in the long term. In our
study, the patients who presented with proteinuria .7 g/
day at the time of diagnosis were more likely to experience
relapse. The clinical parameter most related to relapse in
other studies was age, indicating that younger patients
relapse more frequently than older patients (6,12); however,
this finding was not made in our sample population.
Glucocorticosteroids remain the first-line treatment for
relapse; however, in frequent relapsing and corticosteroid-
dependent patients, it is necessary to use other immunosup-
pressants to minimize the side effects of the prolonged use of
glucocorticosteroids. Eguchi A et al. demonstrated that the
combined use of low-dose cyclosporine and prednisone was
as effective at inducing remission as the use of prednisone
(1 mg/kg/day) alone (13). Even without proper knowledge
of the pathophysiology of MCD, treatment with glucocorti-
costeroids or calcineurin inhibitors can be effective at
inducing remission, but these drugs do not prevent relapses
in most cases. One of the theories regarding the pathophy-
siology of this disease is the dysfunction of podocytes with an
overexpression of angiopoetin-like-4 (ANGPTL4) and CD80
(14), the latter of which contributes to T-cell dysfunction (15).
In an experimental model, it was found that interleukin-13
acts as a potent stimulator of CD80 expression (16), and this
interleukin is also known for its role in allergic processes (17).
In summary, minimal change disease in adults, in
addition to its nephrotic characteristics, may present with
hematuria, hypertension, and AKI. The treatment response
and disease evolution are generally favorable, but there is a
major risk of relapse. According to the current study,
patients with proteinuria .7 g/day were at risk for relapse.
Although these findings are clinically relevant, interpreta-
tions should be made with caution because this was a
retrospective study and more trials are needed to support
the results.
Table 2 - Clinical variables influencing relapse.
B SE Odds Ratio 95% CI p-value
Age (years) -0.22 0.01 0.97 0.94-1.01 0.26
Serum albumin (mg/dL) -0.40 0.41 0.96 0.43-2.14 0.92
Proteinuria (g/day) 0.21 0.08 1.23 1.04-1.46 0.01
Table 1 - Clinical characteristics of relapsing and non-relapsing patients at diagnosis.
Relapsing (n= 34) Non-relapsing (n = 27) p-value
Age (years) 32.5 (22.5-46.0) 34.0 (23.0-61.0) 0.27
Gender (M/F) 13/21 10/17 0.92
Serum creatinine (mg/dL) 0.9 (0.7-1.3) 0.8 (0.7-1.2) 1.00
Serum albumin (g/dL) 1.8 (1.4-2.2) 1.8 (1.5-2.3) 0.65
Proteinuria (g/day) 8.8 (7.1-12.0) 6.0 (3.6-7.3) 0.001
Cholesterol (mg/dL) 423.0 (344.5-569.0) 439.0 (317.0-509.5) 0.25
Triglycerides (mg/dL) 227 (177-371) 198 (143.5-331.5) 0.26
Hematuria (n/%) 6/17.6 2/7.4 0.23
Hypertension (n/%) 12/35.2 5/18.5 0.14
Acute kidney injury (n/%) 12/35.2 5/18.5 0.14
Follow-up time (months) 24 (12-72) 24 (17-48) 0.58
median (interval between quartiles).
AKI - acute kidney injury.
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Figure 1 - Outcome after initial treatment.
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